共 50 条
Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials
被引:81
|作者:
Sachdeva, Aarti
[1
]
Nagpal, Jitender
[1
]
机构:
[1] Sitaram Bhartia Inst Sci & Res, Dept Clin Epidemiol, New Delhi 110016, India
关键词:
fermented milk;
Helicobacter;
meta-analysis;
yogurt;
BIFIDOBACTERIUM-CONTAINING YOGURT;
GASSERI OLL-2716 LG21;
TRIPLE THERAPY;
DOUBLE-BLIND;
BOVINE LACTOFERRIN;
LACTOBACILLUS-JOHNSONII;
SACCHAROMYCES-BOULARDII;
LACTOBACCILUS-GASSERI;
INFECTION;
SUPPLEMENTATION;
D O I:
10.1097/MEG.0b013e32830d0eff
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Objective To evaluate the effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication. Design Systematic review of randomized controlled trials. Data sources Electronic databases and hand search of reviews, bibliographies of books and abstracts and proceedings of international conferences. Review methods Included trials had to be randomized or quasi-randomized and controlled, using fermented milk-based probiotics in the intervention group, treating Helicobacter-infected patients and evaluating improvement or eradication of H. pylori as an outcome. Results The search identified 10 eligible randomized controlled trials. Data were available for 963 patients, of whom 498 were in the treatment group and 465 in the control group. The pooled odds ratio (studies n=9) for eradication by intention-to-treat analysis in the treatment versus control group was 1.91 (1.38-2.67; P<0.0001) using the fixed effects model; test for heterogeneity (Cochran's Q=5.44; P=0.488). The pooled risk difference was 0.10 (95% Cl 0.05-0.15; P<0.0001) by the fixed effects model (Cochran's Q= 13.41; P=0.144). The pooled odds ratio for the number of patients with any adverse effect was 0.51 (95% Cl 0.10-2.57; P=0.41; random effects model; heterogeneity by Cochran's 0=68.5; P<0.0001). Conclusion Fermented milk-based probiotic preparations improve H. pylori eradication rates by approximately 5-15%, whereas the effect on adverse effects is heterogeneous. Eur J Gastroenterol Hepatol 21:45-53 (C) 2009 Wolters Kluwer Health I Lippincott Williams & Wilkins.
引用
收藏
页码:45 / 53
页数:9
相关论文